Aerovate Therapeutics
AVTE

$2.01

7.81%

Market Cap: 57.9M

About: Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Employees: 51

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 8 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

32% more capital invested

Capital invested by funds: $640M [Q4 2023] → $841M (+$201M) [Q1 2024]

27% more funds holding

Funds holding: 63 [Q4 2023] → 80 (+17) [Q1 2024]

20% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 6 (+1) [Q1 2024]

0.05% less ownership

Funds ownership: 102.14% [Q4 2023] → 102.09% (-0.05%) [Q1 2024]

21% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 24

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$2

0%

upside

Avg. target

$29

1,324%

upside

High target

$65

3,134%

upside

8 analyst ratings

5 positive

63%

3 neutral

38%

0 negative

0%

Evercore ISI Group Liisa Bayko	1%downside $2	In-Line Downgraded	18 Jun 2024
Wells Fargo Tiago Fauth	1%downside $2	Equal-Weight Downgraded	18 Jun 2024
Jefferies Eun Yang	1%downside $2	Hold Downgraded	17 Jun 2024
Wedbush Laura Chico	1,940%upside $41	Outperform Reiterated	6 Jun 2024
Wedbush Laura Chico	1,940%upside $41	Outperform Reiterated	22 May 2024

See Analyst Rankings

Financial journalist opinion

Aerovate Therapeutics to Explore Strategic Alternatives

WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

Aerovate Therapeutics to Explore Strategic Alternatives

The 3 Hottest Stock Downgrades From Last Week

Wall Street's leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies and solid corporate earnings growth, analysts expect the S&P 500 to consolidate its gains above 5500.

The 3 Hottest Stock Downgrades From Last Week

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC

ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial and stated that “the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension (“PVR”) compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance.” Following this news, the price of the Company's stock dropped.

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

Zacks Investment Research

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton

BOSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE) for potential securities law violations. Investors who have lost money in their Aerovate Therapeutics investment should contact the firm to learn more about how they might recover those losses.

SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton

Investors Business Daily

Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke

Aerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock plummeted 90%.

Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension.

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today presented a poster outlining baseline characteristics from all patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) at the American Thoracic Society (ATS) 2024 International Conference taking place in San Diego, CA.

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

See News Rankings